International Consensus Criteria: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Add clean-up tag)
(add headings & citations)
Line 1: Line 1:
{{Cleanup | reason=Remove copy-paste text and write content in encyclopedia format, only using quotes where specifically needed. | date=April 2016}}
{{Cleanup | reason=Remove copy-paste text and write content in encyclopedia format, only using quotes where specifically needed. | date=April 2016}}


The [[myalgic encephalomyelitis]] '''International Consensus Criteria''' is a disease definition.
The [[Myalgic Encephalomyelitis]] '''International Consensus Criteria'''<ref name="ICC2011criteria"/> is a medical case definition.
 
==Background and purpose==


The 2012 ICC is very clear on the topic of names:
The 2012 ICC is very clear on the topic of names:
Line 23: Line 25:
5. Focus on treatment efficacy: With enhanced understanding of biopathological mechanisms, biomarkers and other components of pathophysiology specific to ME, more focus and research emphasis can target expanding and augmenting treatment efficacy.
5. Focus on treatment efficacy: With enhanced understanding of biopathological mechanisms, biomarkers and other components of pathophysiology specific to ME, more focus and research emphasis can target expanding and augmenting treatment efficacy.


International Consensus Primer (ICP)
==International Consensus Primer (ICP)==


Problem
Problem


Overly inclusive criteria have created misperceptions, fostered cynicism and have had a major negative impact on how ME is viewed by the medical community, patients, their families, as well as the general public. Some medical schools do not include ME in their curriculum with the result that very significant scientific advances and appropriate diagnostic and treatment protocols have not reached many busy medical practitioners. Some doctors may be unaware of the complexity and serious nature of ME. Patients may go undiagnosed and untreated; they may be shunned or isolated.  
Overly inclusive criteria have created misperceptions, fostered cynicism and have had a major negative impact on how ME is viewed by the medical community, patients, their families, as well as the general public. Some medical schools do not include ME in their curriculum with the result that very significant scientific advances and appropriate diagnostic and treatment protocols have not reached many busy medical practitioners. Some doctors may be unaware of the complexity and serious nature of ME. Patients may go undiagnosed and untreated; they may be shunned or isolated.  
   
   
 
==World Health Organisation==
World Health Organisation


The World Health Organisation lists ME and post viral fatigue syndrome under neurological conditions. http://apps.who.int/classifications/icd10/browse/2016/en#/G93.3
The World Health Organisation lists ME and post viral fatigue syndrome under neurological conditions. http://apps.who.int/classifications/icd10/browse/2016/en#/G93.3
Line 37: Line 37:
Importantly, it doesn’t include chronic fatigue syndrome there, or ME/CFS or CFS/ME. Fatigue syndromes are listed in ‘Other neurotic disorders’ http://apps.who.int/classifications/icd10/browse/2016/en#/F48.0
Importantly, it doesn’t include chronic fatigue syndrome there, or ME/CFS or CFS/ME. Fatigue syndromes are listed in ‘Other neurotic disorders’ http://apps.who.int/classifications/icd10/browse/2016/en#/F48.0


 


==Comparison with other criteria==


Recent studies
*Norwegian researchers compare the main criteria (Oxford, Fukuda, Canadian, International Consensus and SEID). They say "it is important to distinguish between myalgic encephalomyelitis and chronic fatigue syndrome” to improve understanding of the disease, treatment and patients’ lives, as using incorrect criteria can lead to incorrect treatment.<ref name="Egeland2015"/>


A number of scientists have studied the different criteria recently and ME Action has published stories on the topic;
*'Scientists must agree on classifying patients’ Leonard Jason<ref>reference needed</ref>


‘Norwegian researchers ask “What exactly is M.E.?” 2015 which also includes an excellent summary of the main criteria (Oxford, Fukuda, Canadian, International Consensus and SEID). They say "it is important to distinguish between myalgic encephalomyelitis and chronic fatigue syndrome” to improve understanding of the disease, treatment and patients’ lives as using incorrect criteria can lead to ‘incorrect treatment’.
*Frank Twisk explains that ME and CFS are "distinct, partially overlapping, clinical entities such as ME and CFS"Frank Twisk 2016<ref>reference needed</ref>
** Cae2BaLVAAEVfnn.jpg-large.jpg


‘Study says scientists must agree on classifying patients’ on a 2016 paper by Dr Jason and others. Dr Jason is well-respected in the field, has been for a long time and he uses ‘ME and CFS’. Dr Jason is involved in the IACFS/ME (along with Griffith’s Prof Sonya Marshall-Gradisnik, who wrote the criteria that New Zealand use).
==References==
<references>


Twisk’s paper explains that ME and CFS are similar, overlapping but not the same: "distinct, partially overlapping, clinical entities such as ME and CFS”  and this diagram came from his 2016 paper:
<!-- ....1....+....2....+....3....+....4....+....5....+....6....+....7....+....8....+....9....+....0 --->


<ref name="Egeland2015">{{citation
| last1  = Egeland          | first1 = T                  | authorlink1 = Torstein Egeland
| last2  = Angelsen        | first2 = A                  | authorlink2 = Arild Angelsen
| last3  = Haug            | first3 = R                  | authorlink3 = Ruth Haug
| last4  = Henriksen        | first4 = JO                | authorlink4 = Jan-Olave Henriksen
| last5  = Lea              | first5 = TE                | authorlink5 = Tor Erling Lea
| last6  = Saugstad        | first6 = OD                | authorlink6 = Ola Didrik Saugstad
| title  = What exactly is myalgic encephalomyelitis?
| type    = Perspectives
| journal = Tidsskr Nor Legeforen | volume = 2015 | issue = 135 | page = 1756–9
| date    = Oct 2015
| doi    = 10.4045/tidsskr.15.0089
| url    = http://tidsskriftet.no/article/3404849/en_GB
| lay-url = http://www.meaction.net/2015/12/10/norwegian-researchers-ask-what-exactly-is-m-e/
}}</ref>


Cae2BaLVAAEVfnn.jpg-large.jpg
<ref name="ICC2011criteria">{{citation
| last1  = Carruthers      | first1 = BM                | authorlink1 = Bruce M Carruthers
| last2  = van de Sande    | first2 = MI                | authorlink2 = Marjorie I van de Sande
| last3  = De Meirleir      | first3 = KL                | authorlink3 = Kenny L De Meirleir
| last4  = Klimas          | first4 = NG                | authorlink4 = Nancy G Klimas
| last5  = Broderick        | first5 = G                  | authorlink5 = Gordon Broderick
| last6  = Mitchell        | first6 = T                  | authorlink6 = Terry Mitchell
| last7  = Staines          | first7 = D                  | authorlink7 = Donald Staines
| last8  = Powles          | first8 = ACP                | authorlink8 = A C Peter Powles
| last9  = Speight          | first9 = N                  | authorlink9 = Nigel Speight
| last10  = Vallings        | first10= R                  | authorlink10= Rosamund Vallings
| last11  = Bateman          | first11= L                  | authorlink11= Lucinda Bateman
| last12  = Baumgarten-Austrheim  | first12= B            | authorlink12= Barbara Baumgarten-Austrheim
| last13  = Bell            | first13= DS                | authorlink13= David S Bell
| last14  = Carlo-Stella    | first14= N                  | authorlink14= Nicoletta Carlo-Stella
| last15  = Chia            | first15= J                  | authorlink15= John Chia
| last16  = Darragh          | first16= A                  | authorlink16= Austin Darragh
| last17  = Jo              | first17= D                  | authorlink17= Daehyun Jo
| last18  = Lewis            | first18= DP                | authorlink18= Donald P Lewis
| last19  = Light            | first19= AR                | authorlink19= Alan R Light
| last20  = Marshall-Gradisnik  | first20= S              | authorlink20= Sonya Marshall-Gradisnik
| last21  = Mena            | first21= I                  | authorlink21= Ismael Mena
| last22  = Mikovits        | first22= JA                | authorlink22= Judy A Mikovits
| last23  = Miwa            | first23= K                  | authorlink23= Kunihisa Miwa
| last24  = Murovska        | first24= M                  | authorlink24= Modra Murovska
| last25  = Pall            | first25= ML                | authorlink25= Martin L Pall
| last26  = Stevens          | first26= SR                | authorlink26= Staci R Stevens
| title  = Myalgic encephalomyelitis: International Consensus Criteria
| journal = Journal of Internal Medicine | volume = Volume 270, Issue 4 | page = pages 327–338
| date    = 22 August 2011
| pmid    = 21777306  | doi = 10.1111/j.1365-2796.2011.02428.x
| url    = http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2011.02428.x/full
}}</ref>




==The definition==
{{Citation
| last1  = Carruthers
| first1 = B. M.
| authorlink1 =
| last2  = van de Sande
| first2 = M. I.
| authorlink2 =
| last3  = De Meirleir
| first3 = K. L.
| authorlink3 = Kenny De Meirleir
| last4  = Klimas
| first4 = N. G.
| authorlink4 = Nancy Klimas
| last5  = Broderick
| first5 = G.
| authorlink5 = Gordon Broderick
| last6  = Mitchell
| first6 = T.
| authorlink6 =
| last7 = Staines
| first7 = D.
| authorlink7 = Donald Staines
| last8 = Powles
| first8 = A. C. P.
| authorlink8 =
| last9  = Speight
| first9 = N.
| authorlink9 = Nigel Speight
| last10  = Vallings
| first10 = R.
| authorlink10 = Rosamund Vallings
| last11  = Bateman
| first11 = L.
| authorlink11 = Lucinda Bateman
| last12 = Baumgarten-Austrheim
| first12 = B. 
| authorlink12 =
| last13 = Bell
| first13 = D. S. 
| authorlink13 = David Bell
| last14 = Carlo-Stella
| first14 = N. 
| authorlink14 =
| last15 = Chia
| first15 = J. 
| authorlink15 = John Chia
| last16 = Darragh
| first16 = A. 
| authorlink16 =
| last17 = Jo
| first17 = D. 
| authorlink17 =
| last18 = Lewis
| first18 = D. 
| authorlink18 = Donald P Lewis
| last19 = Light
| first19 = A. R. 
| authorlink19 = Alan Light
| last20 = Marshall-Gradisnik
| first20 = S. 
| authorlink20 = Sonya Marshall-Gradisnik
| last21 = Mena
| first21 = I. 
| authorlink21 =
| last22 = Mikovits
| first22 = J. A. 
| authorlink22 = Judy Mikovits
| last23 = Miwa
| first23 =  K.
| authorlink23 =
| last24 = Murovska
| first24 = M. 
| authorlink24 =
| last25 = Pall
| first25 = M. L. 
| authorlink25 = Martin Pall
| last26 = Stevens
| first26 = S. 
| authorlink26 = Staci Stevens
| display-authors = 26
| title = Myalgic encephalomyelitis: International Consensus Criteria
| journal = Journal of Internal Medicine
| year  = 2011
| pmid = 21777306
| doi  = 10.1111/j.1365-2796.2011.02428.x
}}


[[Category:Definitions]]
[[Category:Definitions]]

Revision as of 21:03, May 4, 2016

The Myalgic Encephalomyelitis International Consensus Criteria[1] is a medical case definition.

Background and purpose[edit | edit source]

The 2012 ICC is very clear on the topic of names:

Problem

The label ‘chronic fatigue syndrome’ (CFS), coined in the 1980s, has persisted due to lack of knowledge of its etiologic agents and pathophysiology. Misperceptions have arisen because the name ‘CFS’ and its hybrids ME/CFS, CFS/ME and CFS/CF have been used for widely diverse conditions. Patient sets can include those who are seriously ill with ME, many bedridden and unable to care for themselves, to those who have general fatigue or, under the Reeves criteria, patients are not required to have any physical symptoms. There is a poignant need to untangle the web of confusion caused by mixing diverse and often overly inclusive patient populations in one heterogeneous, multi-rubric pot called ‘chronic fatigue syndrome’. We believe this is the foremost cause of diluted and inconsistent research findings, which hinders progress, fosters scepticism, and wastes limited research monies.

Solution

The rationale for the development of the ICC was to utilize current research knowledge to identify objective, measurable and reproducible abnormalities that directly reflect the interactive, regulatory components of the underlying pathophysiology of ME. Specifically, the ICC select patients who exhibit explicit multi-systemic neuropathology, and have a pathological low threshold of physical and mental fatigability in response to exertion. Cardiopulmonary exercise test- retest studies have confirmed many post-exertional abnormalities. Criterial symptoms are compulsory and identify patients who have greater physical, cognitive and functional impairments. The ICC advance the successful strategy of the Canadian Consensus Criteria (CCC) of grouping coordinated patterns of symptom clusters that identify areas of pathology. The criteria are designed for both clinical and research settings.

1. Name: Myalgic encephalomyelitis, a name that originated in the 1950s, is the most accurate and appropriate name because it reflects the underlying multi-system pathophysiology of the disease. Our panel strongly recommends that only the name ‘myalgic encephalomyelitis’ be used to identify patients meeting the ICC because a distinctive disease entity should have one name. Patients diagnosed using broader or other criteria for CFS or its hybrids (Oxford, Reeves, London, Fukuda, CCC, etc.) should be reassessed with the ICC. Those who fulfill the criteria have ME; those who do not would remain in the more encompassing CFS classification. (bold emphasis mine)

2. Remove patients who satisfy the ICC from the broader category of CFS. The purpose of diagnosis is to provide clarity. The criterial symptoms, such as the distinctive abnormal responses to exertion can differentiate ME patients from those who are depressed or have other fatiguing conditions. Not only is it common sense to extricate ME patients from the assortment of conditions assembled under the CFS umbrella, it is compliant with the WHO classification rule that a disease cannot be classified under more than one rubric. The panel is not dismissing the broad components of fatiguing illnesses, but rather the ICC are a refinement of patient stratification. As other identifiable patient sets are identified and supported by research, they would then be removed from the broad CFS/CF category.

Research on ME: The logical way to advance science is to select a relatively homogeneous patient set that can be studied to identify biopathological mechanisms, biomarkers and disease process specific to that patient set, as well as comparing it to other patient sets. It is counterproductive to use inconsistent and overly inclusive criteria to glean insight into the pathophysiology of ME if up to 90% of the research patient sets may not meet its criteria (Jason 2009). Research on other fatiguing illnesses, such as cancer and multiple sclerosis (MS), is done on patients who have those diseases. There is a current, urgent need for ME research using patients who actually have ME. (bold emphasis mine)

4. Research confirmation: When research is applied to patients satisfying the ICC, previous findings based on broader criteria will be confirmed or refuted. Validation of ME being a differential diagnosis, as is multiple sclerosis (MS), or a subgroup of chronic fatigue syndrome, will then be verified.

5. Focus on treatment efficacy: With enhanced understanding of biopathological mechanisms, biomarkers and other components of pathophysiology specific to ME, more focus and research emphasis can target expanding and augmenting treatment efficacy.

International Consensus Primer (ICP)[edit | edit source]

Problem

Overly inclusive criteria have created misperceptions, fostered cynicism and have had a major negative impact on how ME is viewed by the medical community, patients, their families, as well as the general public. Some medical schools do not include ME in their curriculum with the result that very significant scientific advances and appropriate diagnostic and treatment protocols have not reached many busy medical practitioners. Some doctors may be unaware of the complexity and serious nature of ME. Patients may go undiagnosed and untreated; they may be shunned or isolated.

World Health Organisation[edit | edit source]

The World Health Organisation lists ME and post viral fatigue syndrome under neurological conditions. http://apps.who.int/classifications/icd10/browse/2016/en#/G93.3

Importantly, it doesn’t include chronic fatigue syndrome there, or ME/CFS or CFS/ME. Fatigue syndromes are listed in ‘Other neurotic disorders’ http://apps.who.int/classifications/icd10/browse/2016/en#/F48.0


Comparison with other criteria[edit | edit source]

  • Norwegian researchers compare the main criteria (Oxford, Fukuda, Canadian, International Consensus and SEID). They say "it is important to distinguish between myalgic encephalomyelitis and chronic fatigue syndrome” to improve understanding of the disease, treatment and patients’ lives, as using incorrect criteria can lead to incorrect treatment.[2]
  • 'Scientists must agree on classifying patients’ Leonard Jason[3]
  • Frank Twisk explains that ME and CFS are "distinct, partially overlapping, clinical entities such as ME and CFS"Frank Twisk 2016[4]
    • Cae2BaLVAAEVfnn.jpg-large.jpg

References[edit | edit source]

<references>


[2]

[1]